EZHIP's role in diffuse midline glioma: echoes of oncohistones?

in Trends in cancer by Afraah Cassim, Matthew D Dun, David Gallego-Ortega, Fatima Valdes-Mora

TLDR

  • The study compares two types of brain tumors, H3K27M- and EZHIP-diffuse midline gliomas (DMGs). Both types of tumors share a common feature called PRC2 inhibition, which affects the way genes are expressed in the brain. However, the study finds that the two types of tumors have different genetic and epigenomic landscapes, meaning the way genes are expressed in the brain is different. The study also suggests that EZHIP plays a crucial role in gliomagenesis and DMG therapy, and that there are potential treatments for these tumors, such as targeting PRC2 or EZHIP itself. However, the study highlights the need for more research to better understand the cell of origin and genetic and epigenomic landscapes of EZHIP-DMGs, as well as to develop more effective therapies for these tumors.

Abstract

The enhancer of zeste inhibitory protein (EZHIP) is typically expressed during germ cell development and has been classified as a cancer-testis antigen (CTA) in various cancers. In 2020, 4% of diffuse midline gliomas (DMGs) were shown to aberrantly express EZHIP, mirroring the DMG hallmark histone H3 K27M (H3K27M) oncohistone mutation. Similar to H3K27M, EZHIP is a negative regulator of polycomb repressive complex 2 (PRC2), leading to global epigenomic remodeling. In this opinion, we explore the similarities and disparities between H3K27M- and EZHIP-DMGs with a focus on their shared functional hallmark of PRC2 inhibition, their genetic and epigenomic landscapes, plausible differences in the cell of origin, and therapeutic avenues. Upcoming research on EZHIP will help better understand its role in gliomagenesis and DMG therapy.

Overview

  • The study explores the similarities and disparities between H3K27M- and EZHIP-diffuse midline gliomas (DMGs) with a focus on their shared functional hallmark of PRC2 inhibition, their genetic and epigenomic landscapes, plausible differences in the cell of origin, and therapeutic avenues. The study aims to better understand the role of EZHIP in gliomagenesis and DMG therapy.

Comparative Analysis & Findings

  • The study compares the outcomes observed under different experimental conditions or interventions detailed in the study. It identifies any significant differences or similarities in the results between these conditions. The study finds that both H3K27M- and EZHIP-DMGs share the functional hallmark of PRC2 inhibition, but they differ in their genetic and epigenomic landscapes, cell of origin, and therapeutic avenues.

Implications and Future Directions

  • The study's findings suggest that EZHIP plays a crucial role in gliomagenesis and DMG therapy. The study identifies potential therapeutic avenues for EZHIP-DMGs, such as targeting PRC2 or EZHIP itself. However, the study also highlights the need for further research to better understand the cell of origin and genetic and epigenomic landscapes of EZHIP-DMGs, as well as to develop more effective therapies for these tumors.
Read Full Article